ERBB2 and cancer: In luminal disease, combined features of immunity and tumoral characteristics, like for example tumor cell proliferation or histological grade, may be probably the best approach, while in TNBC and HER2+ disease immunity is probably sufficient to predict outcome, with cancer cell characteristics being less important in these subtypes.